Investigation of the Effects of Deep Eutectic Solvents Based on Fructose, Sucrose, and Glycerol on the Kinetic Parameters of Uricase
Keywords:
Uricase, Deep Eutectic Solvent, Catalytic Efficiency, Kinetic ParametersAbstract
Urate oxidase (Uricase), an important enzyme in the fields of industry and pharmaceuticals, plays a significant role in the conversion of uric acid to allantoin and the reduction of serum uric acid levels. This has led to increased interest among researchers in the stabilization of this enzyme. One effective method for stabilizing uricase involves the use of deep eutectic solvents (DES). In the present study, conducted at the Graduate University of Advanced Technology in Kerman, we cultured the BL21 bacteria and expressed and purified recombinant uricase. The impact of a glycerol-based eutectic solvent combined with the sugars fructose and sucrose on the enzyme's kinetic parameters was examined. The results indicated that the eutectic solvent reduced the Michaelis constant (Km) and enhanced the catalytic efficiency of the enzyme in the presence of the eutectic compared to the free enzyme. This solvent, with its hydroxyl groups and influence on the enzyme's intramolecular hydrogen bonds, significantly improved the enzyme's kinetic stability.
Downloads
References
[1] F. Dabbagh, M. B. Ghoshoon, S. Hemmati, M. Zamani, M. Mohkam, and Y. Ghasemi, "Engineering
Human Urate Oxidase: Towards Reactivating It as an Important Therapeutic Enzyme," (in eng),
Curr Pharm Biotechnol, vol. 17, no. 2, pp. 141-6, 2015, doi:
10.2174/1389201016666150907113055.
[2] L. Gabison, N. Colloc'h, and T. Prangé, "Azide inhibition of urate oxidase," (in eng), Acta
Crystallogr F Struct Biol Commun, vol. 70, no. Pt 7, pp. 896-902, Jul 2014, doi:
10.1107/s2053230x14011753.
[3] G. Artioli, N. Masciocchi, and E. Galli, "The Elusive Crystal Structure of Uric Acid Dihydrate:
Implication for Epitaxial Growth During Biomineralization," Acta Crystallographica Section Bstructural Science - ACTA CRYSTALLOGR B-STRUCT SCI, vol. 53, pp. 498-503, 06/01 1997, doi:
10.1107/S0108768196013067.
[4] H. A. Sathish, P. R. Kumar, and V. Prakash, "Mechanism of solvent induced thermal stabilization of
papain," (in eng), Int J Biol Macromol, vol. 41, no. 4, pp. 383-90, Oct 1 2007, doi:
10.1016/j.ijbiomac.2007.05.009.
[5] V. Vagenende, M. G. Yap, and B. L. Trout, "Mechanisms of protein stabilization and prevention of
protein aggregation by glycerol," (in eng), Biochemistry, vol. 48, no. 46, pp. 11084-96, Nov 24
2009, doi: 10.1021/bi900649t.
[6] S. Naseem and A. King, "Ammonia production in poultry houses can affect health of humans, birds,
and the environment—techniques for its reduction during poultry production," Environmental
Science and Pollution Research, vol. 25, 06/01 2018, doi: 10.1007/s11356-018-2018-y.
[7] M. R. Sherman, M. G. P. Saifer, and F. Perez-Ruiz, "PEG-uricase in the management of treatmentresistant gout and hyperuricemia," Advanced Drug Delivery Reviews, vol. 60, no. 1, pp. 59-68,
2008/01/03/ 2008, doi: https://doi.org/10.1016/j.addr.2007.06.011.
[8] C. Chen, J.-M. Lü, and Q. Yao, "Hyperuricemia-Related Diseases and Xanthine Oxidoreductase
(XOR) Inhibitors: An Overview," Medical Science Monitor, vol. 22, pp. 2501-2512, 07/17 2016, doi:
10.12659/MSM.899852.
[9] J. Maiuolo, F. Oppedisano, S. Gratteri, C. Muscoli, and V. Mollace, "Regulation of uric acid
metabolism and excretion," (in eng), Int J Cardiol, vol. 213, pp. 8-14, Jun 15 2016, doi:
10.1016/j.ijcard.2015.08.109.
[10] M. Jin et al., "Uric acid, hyperuricemia and vascular diseases," (in eng), Front Biosci (Landmark
Ed), vol. 17, no. 2, pp. 656-69, Jan 1 2012, doi: 10.2741/3950.
[11] H. R. Schumacher, Jr. and L. X. Chen, "Newer therapeutic approaches: gout," (in eng), Rheum Dis
Clin North Am, vol. 32, no. 1, pp. 235-44, xii, Feb 2006, doi: 10.1016/j.rdc.2005.10.003.
[12] A. Pession, F. Melchionda, and C. Castellini, "Pitfalls, prevention, and treatment of hyperuricemia
during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)," (in eng),
Biologics, vol. 2, no. 1, pp. 129-41, Mar 2008, doi: 10.2147/btt.s1522.
[13] G. B. Elion, A. Kovensky, and G. H. Hitchings, "Metabolic studies of allopurinol, an inhibitor of
xanthine oxidase," (in eng), Biochem Pharmacol, vol. 15, no. 7, pp. 863-80, Jul 1966, doi:
10.1016/0006-2952(66)90163-8.
[14] M. D. Sanchez-Niño et al., "Lesinurad: what the nephrologist should know," (in eng), Clin Kidney J,
vol. 10, no. 5, pp. 679-687, Oct 2017, doi: 10.1093/ckj/sfx036.
[15] H. J. Ryu et al., "Clinical risk factors for adverse events in allopurinol users," (in eng), J Clin
Pharmacol, vol. 53, no. 2, pp. 211-6, Feb 2013, doi: 10.1177/0091270012439715.
[16] M. London and P. B. Hudson, "Uricolytic activity of purified uricase in two human beings," (in
eng), Science, vol. 125, no. 3254, pp. 937-8, May 10 1957, doi: 10.1126/science.125.3254.937.
[17] D. Anandkumar, G. Guntuku, S. Gurugubelli, S. Basha, and V. Sandeep, "Review of Uricase and
Other Key Metabolites Produced by Microorganisms through Submerged Fermentation
INTRODUCTION," YMER Digital, vol. 22, pp. 1500-17, 10/12 2023.
[18] J. D. Moolenburgh, M. K. Reinders, and T. L. Jansen, "Rasburicase treatment in severe tophaceous
gout: a novel therapeutic option," (in eng), Clin Rheumatol, vol. 25, no. 5, pp. 749-52, Sep 2006,
doi: 10.1007/s10067-005-0043-y.
[19] L. D. Kennedy and V. O. Ajiboye, "Rasburicase for the prevention and treatment of hyperuricemia
in tumor lysis syndrome," Journal of Oncology Pharmacy Practice, vol. 16, no. 3, pp. 205-213,
2010/09/01 2009, doi: 10.1177/1078155209348719.
[20] G. Alvaro, R. Fernandez-Lafuente, R. M. Blanco, and J. M. Guisán, "Immobilization-stabilization of
Penicillin G acylase fromEscherichia coli," Applied Biochemistry and Biotechnology, vol. 26, no. 2,
pp. 181-195, 1990/11/01 1990, doi: 10.1007/BF02921533.
[21] R. J. Johnson et al., "Essential hypertension, progressive renal disease, and uric acid: a
pathogenetic link?," Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 1909-1919,
2005.
[22] M. H. Alderman, H. Cohen, S. Madhavan, and S. Kivlighn, "Serum uric acid and cardiovascular
events in successfully treated hypertensive patients," (in eng), Hypertension, vol. 34, no. 1, pp. 144-
50, Jul 1999, doi: 10.1161/01.hyp.34.1.144.
[23] S. Ohtake, Y. Kita, and T. Arakawa, "Interactions of formulation excipients with proteins in solution
and in the dried state," (in eng), Adv Drug Deliv Rev, vol. 63, no. 13, pp. 1053-73, Oct 2011, doi:
10.1016/j.addr.2011.06.011.
[24] S. Jevsevar, M. Kunstelj, and V. G. Porekar, "PEGylation of therapeutic proteins," (in eng),
Biotechnol J, vol. 5, no. 1, pp. 113-28, Jan 2010, doi: 10.1002/biot.200900218.
[25] L. Tran, S. Das, L. Zhao, M. G. Finn, and E. A. Gaucher, "Oral Delivery of Nanoparticles Carrying
Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice," (in eng),
Biomacromolecules, vol. 24, no. 5, pp. 2003-2008, May 8 2023, doi: 10.1021/acs.biomac.2c01388.
[26] S. O. Pustake, P. K. Bhagwat, and P. B. Dandge, "Statistical media optimization for the production
of clinical uricase from Bacillus subtilis strain SP6," (in eng), Heliyon, vol. 5, no. 5, p. e01756, May
2019, doi: 10.1016/j.heliyon.2019.e01756.
[27] J. F. Back, D. Oakenfull, and M. B. Smith, "Increased thermal stability of proteins in the presence of
sugars and polyols," (in eng), Biochemistry, vol. 18, no. 23, pp. 5191-6, Nov 13 1979, doi:
10.1021/bi00590a025.
[28] I. Mikaelian and A. Sergeant, "A general and fast method to generate multiple site directed
mutations," (in eng), Nucleic Acids Res, vol. 20, no. 2, p. 376, Jan 25 1992, doi:
10.1093/nar/20.2.376.
[29] A. P. Abbott, D. Boothby, G. Capper, D. L. Davies, and R. K. Rasheed, "Deep eutectic solvents
formed between choline chloride and carboxylic acids: versatile alternatives to ionic liquids," (in
eng), J Am Chem Soc, vol. 126, no. 29, pp. 9142-7, Jul 28 2004, doi: 10.1021/ja048266j.
[30] C. Velez and O. Acevedo, "Simulation of deep eutectic solvents: Progress to promises," Wiley
Interdisciplinary Reviews: Computational Molecular Science, vol. 12, no. 4, p. e1598, 2022.
[31] E. L. Smith, A. P. Abbott, and K. S. Ryder, "Deep eutectic solvents (DESs) and their applications,"
Chemical reviews, vol. 114, no. 21, pp. 11060-11082, 2014.
[32] P. Shahmoradipour, M. Zaboli, and M. Torkzadeh-Mahani, "Exploring the impact of taurine on the
biochemical properties of urate oxidase: response surface methodology and molecular dynamics
simulation," Journal of Biological Engineering, vol. 18, no. 1, p. 10, 2024/01/22 2024, doi:
10.1186/s13036-023-00397-x.
[33] J. Li et al., "High-level expression, purification, and characterization of non-tagged Aspergillus
flavus urate oxidase in Escherichia coli," (in eng), Protein Expr Purif, vol. 49, no. 1, pp. 55-9, Sep
2006, doi: 10.1016/j.pep.2006.02.003.
[34] L. Cai, Q. Li, Y. Deng, X. Liu, W. Du, and X. Jiang, "Construction and expression of recombinant
uricase‑expressing genetically engineered bacteria and its application in rat model of
hyperuricemia," (in eng), Int J Mol Med, vol. 45, no. 5, pp. 1488-1500, May 2020, doi:
10.3892/ijmm.2020.4512.
[35] A. Teimoori, H. Soleimanjahi, F. Fotouhi, and Z. Meshkat, "Isolation and cloning of human
papillomavirus 16 L1 gene from Iranian isolate," Saudi medical journal, vol. 29, pp. 1105-8, 09/01
2008.
[36] [Online]. Available: https://www.eurofins.in/genomics/blog/advantage-of-expression-cloning-inpet28a-plus-vector/.
[37] M. Pazhang, K. Khajeh, and B. Ranjbar, "Effects of water-miscible solvents and polyhydroxy
compounds on the structure and enzymatic activity of TLN," Journal of biotechnology, vol. 127, pp.
45-53, 01/01 2007, doi: 10.1016/j.jbiotec.2006.05.017.
[38] T.-Y. Lin and S. N. Timasheff, "Why do some organisms use a urea-methylamine mixture as
osmolyte? Thermodynamic compensation of urea and trimethylamine N-oxide interactions with
protein," Biochemistry, vol. 33, no. 42, pp. 12695-12701, 1994/10/01 1994, doi:
10.1021/bi00208a021.
[39] Z. Taherimehr, M. Zaboli, and M. Torkzadeh-Mahani, "New insight into the molecular mechanism
of the trehalose effect on urate oxidase stability," (in eng), J Biomol Struct Dyn, vol. 40, no. 4, pp.
1461-1471, Mar 2022, doi: 10.1080/07391102.2020.1828167
